We used immunohistochemistry with antibodies to Ki67, a marker of cell proliferation, to estimate the frequency of proliferating cells in tumor sections from all 4 treatment-groups (Figure 7, Ki67 IHC). This evidence concerns the gene MKI67 and neoplasm.